Modulating VEGF Bioavailability via Soluble Receptor Decoys
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to modulate angiogenic growth factor bioavailability and activity, particularly for conditions associated with decreased vascularity such as ocular disorders, preeclampsia, and cardiovascular disorders, where regulating VEGF and PlGF interactions is desirable.
Innovation Solution
Development of compounds and compositions that modulate the bioavailability and activity of VEGF and PlGF by regulating interactions with inactivating agents, including nucleic acid molecules and antibodies that bind to VEGF or PlGF, or by using siRNA to down-regulate the expression of VEGF receptors, thereby inhibiting the formation of growth factor-inactivating agent complexes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are used to modulate VEGF bioavailability by regulating interactions with inactivating agents, then VEGF bioavailability and vascularization are improved, but the complexity of the treatment mechanism increases
Solution Approach 1:
The patent uses soluble VEGF receptors (sVEGFR-1 and sVEGFR-2) as intermediary molecules that mediate the interaction between VEGF and its signaling pathways. These soluble receptors act as decoys that bind VEGF with high affinity, preventing it from binding to cell surface receptors and thereby modulating VEGF bioavailability in a controlled manner.
Solution Approach 2:
The patent employs siRNA technology to change the expression parameters of VEGF receptors at the genetic level. By introducing small interfering RNA molecules that target specific VEGF receptor mRNAs, the system dynamically adjusts the quantity of functional receptors on cell surfaces, thereby controlling VEGF signaling intensity and bioavailability.
2Difficulty of detecting and measuring
If siRNA is used to down-regulate VEGF receptor expression, then VEGF signaling is inhibited, but the specificity and precision of gene targeting increase
Solution Approach 1:
The patent segments the VEGF receptor family into distinct targets by designing separate siRNA molecules for VEGFR-1 and VEGFR-2. This segmentation allows selective down-regulation of specific receptor isoforms while preserving others, enabling precise control over different VEGF signaling pathways and reducing off-target effects.
Solution Approach 2:
The patent implements a feedback mechanism where siRNA expression is controlled by promoters that respond to VEGF signaling activity. When VEGF levels are high, the promoter activates siRNA transcription, which then down-regulates VEGF receptors and reduces signaling, creating a negative feedback loop that maintains homeostasis and prevents over-suppression.
Data Source
AI summary
This invention relates to compounds, compositions, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.